Transition Therapeutics, Inc.
Transition Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapeutics for disease indications with large markets. It operates through research and development of therapeutic agents segment. The company's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada.